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Rezumat
Boala fi catului gras nealcoolic: noi abordări tera-
peutice
Boala fi catului gras nealcoolic (BFGNA) este cea mai 
răspândită maladie hepatică în lumea occidentală, cu 
o prevalenţă de 20-33% în populaţia generală. Epide-
miologia globală a BFGNA devine tot mai cunoscută, 
însă o farmacoterapie precisă nu a fost încă stabilită. 
Tratamentul cu statine este adeseori evitat la bolnavii 
cu o BFGNA, iar medicii sunt îngrijoraţi de prescrierea 
statinelor la pacienţii cu valoarea crescută inexplicabilă 
a enzimelor hepatice sau cu o maladie hepatică activă. 
Monocolinele acţionează ca inhibitori reversibili ai 
reductazei 3-hidroxi-3-metil-glutaril-coenzimă A, reduc 
concentraţiile de colesterol şi sunt capabile să scadă 
nivelul de lipoproteine cu densitate mică. Noi abordări 
în terapia BFGNA ce vizează metabolismul colesterolu-
lui pot deveni utile pentru a reduce grăsimea hepatică, 
astfel diminuând leziunile hepatice în aceste maladii.
Cuvinte-cheie: boala fi catului gras nealcoolic, dislipi-
demie, statine, monocoline
Резюме
Новый терапевтический подход при неалкоголь-
ной жирной болезни печени
Безалкогольная жирная болезнь печени (БАЖБП) 
является наиболее распространенным заболеванием 
печени в западных странах (до 20-33% из общей 
популяции). Несмотря на растущее понимание 
глобальной эпидемии БАЖБП, до сих пор нет опре-
деленной фармакотерапии для этого заболевания. 
Очень часто статины не используются у пациентов 
с БАЖБП и многие врачи обеспокоены назначением 
статинов пациентам с необъяснимым постоян-
ным повышением ферментов печени или активным 
заболеванием печени. Моноколины действуют 
как обратимые ингибиторы 3-гидрокси-3-метил-
глутарил-кофермент-редуктазы, снижают концен-
трацию холестерина и способны уменьшать уровень 
липопротеинов низкой плотности. Новые подходы в 
терапии БАЖБП, влияющие на метаболизм холесте-
рина, могут стать полезными для снижения уровня 
жировой инфильтрации в печени, что уменьшает 
повреждение печени при этой патологии.
Ключевые слова: неалкогольная жирная болезнь 
печени, дислипидемия, статины, моноколин
Introduction
Non-alcoholic fatty liver disease (NAFLD) is 
the most common liver disease in the western 
world with prevalence of 20–33% in general 
population, encompasses a spectrum of hepatic 
histopathological changes ranging from non-
inflammatory intracellular fat deposition to 
non-alcoholic steatohepatitis (NASH), which 
may progress into hepatic fibrosis, cirrhosis, or 
hepatocellular carcinoma. NAFLD is associated 
with metabolic syndrome, type 2 diabetes mel-
litus and increased cardiovascular disease (CVD) 
which contribute to the morbidity and mortality 
besides that due to hepatic disease.
Despite growing understanding of the 
global epidemic of NAFLD, there is no definite 
pharmacotherapy available. Most available data 
on pharmacologic interventions consists of small 
nonrandomized studies, which lack a control 
group and histological evaluation. This review 
article will evaluate   the current evidence on 
pharmacological and nonpharmacological thera-
peutic options of NAFLD, and highlight adminis-
tration of statins and natural statins (monocoline) 
effect in patient with NAFLD.
I. Non pharmacological treatment 
I.1. Lifestyle Intervention. Obesity and meta-
bolic syndrome are the most important risk 
factors for NAFLD [6]. Excessive food intake, 
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particularly western diet that includes complex 
carbohydrates and saturated fats along with 
sedentary lifestyle, has increased the prevalence 
of obesity and metabolic syndrome leading to 
NAFLD. Therefore, lifestyle intervention targeting 
weight loss has been of great interest in terms of 
being a therapeutic option for NAFLD. Neverthe-
less, adjusting such changes to one’s lifestyle and 
achieving the target weight reduction are difficult 
and many factors may play a role. Furthermore, 
weight loss of at least 7% is required for histo-
logical improvement, and greatest improvement 
achieved with >10% weight loss [10]; however, 
only 50% of patients are able to achieve that 
goal.
I.2. Dietary Modification. It is important to 
recognize the role of nutritional imbalance be-
tween saturated and unsaturated fatty acids, as 
well as carbohydrates and proteins, in develop-
ment and progression of NAFLD. Studies show 
that dietary deficiency of polyunsaturated fatty 
acids (PUFA) can lead to NAFLD and patients with 
NASH seem to have overall decreased intake of 
PUFA and increased intake of saturated fat, and 
trans fatty acids. Furthermore, fructose is another 
common ingredient used as sweetener in many 
food products and soft drinks, which is found to 
have a strong association with development of 
metabolic risk factors and 2-3-fold increased risk 
of developing liver steatosis.
I.3. Dietary Modification Plus Physical Activity. 
Dietary modifications such as calorie restriction 
as well as carbohydrate and fat restriction in 
combination with exercise have been assessed 
in multiple studies and combination strategy 
has shown better results. In a prospective study 
involving 261 patients with biopsy proven NASH, 
lifestyle modification with hypocaloric diet and 
moderate intensity exercise show that weight loss 
of >5% was associated with reduction of NASH 
and 90% of the participants with >10% weight 
loss had resolution of NASH [10].
II. Bariatric surgery 
Weight loss through bariatric surgery has 
been proposed as a possible treatment option 
for nonalcoholic fatty liver disease because of 
its positive effect on liver histology. Neverthe-
less, rapid sudden weight loss such as a result of 
bariatric surgery may lead to progression of liver 
failure in some NAFLD patients. A French study 
looked at the metabolic markers and histology 
before bariatric surgery and 1 year and 5 years 
after the surgery in 381 patients with severe 
obesity [7]. This study showed an improvement 
in steatosis, ballooning, and overall NASH with 
significant reduction in percentage of NASH 
patients at 5 years compared to before surgery 
(27,4% to 14,2%). 
III. Pharmacological treatment
III.1. Weight Loss Medication. Orlistat and 
Sibutramine have been studied as a treatment 
option for nonalcoholic fatty liver disease, though 
without much convincing results. Orlistat is a 
pancreatic lipase inhibitor that reduces absorp-
tion of free fatty acids. Sibutramine is a centrally 
acting serotonin-norepinephrine reuptake in-
hibitor, which enhances satiety. In a randomized 
prospective trial, 50 overweight patients with 
biopsy proven NASH were assigned to either 
1400 kcal/day diet plus vitamin E 800 IU alone 
or with combination of orlistat for 9 months 
[4]. Both groups showed reduction in steatosis, 
necroinflammation, ballooning, and NAS in ad-
dition to reduction of weight and improvement 
in aminotransferases.
III.2. Antidiabetic Medications 
III.2.1. Thiazolidinediones (TZDs) are per-
oxisomal proliferator activated receptor (PPAR-) 
gamma agonists that promote hepatic fatty acid 
oxidation, which increases hepatic lipogenesis 
and insulin sensitivity. Most studies have shown 
improved biochemical efficacy with TZDs in 
NAFLD patients and some of them resulted in 
histological improvements such as steatosis and 
inflammation.
III.2.2. Metformin improves insulin resistance 
by reducing hepatic gluconeogenesis and fatty 
acid oxidation, increasing peripheral and hepatic 
insulin sensitivity, decreasing intestinal glucose 
absorption, and lowering serum lipid concentra-
tion. Recent animal studies have also suggested 
a possible role of metformin in prevention of 
hepatocellular carcinoma. Although, some of 
the studies showed improvement in metabolic 
markers, aminotransferases, and liver histology, 
most of the benefits may be due to metformin’s 
known effect of causing improvement in insulin 
sensitivity, weight loss, and other markers of 
metabolic syndrome [5].
III.2.3. Other Antidiabetic Agents Studies 
have been done with meglitinides and incretin 
mimetics (GLP-1 analogs) to assess their effect 
on fatty liver. Meglitinide stimulates pancreatic 
insulin release and pancreatic beta cell growth. 
The data on use of meglitinide as treatment for 
NAFLD/NASH is scarce. Although some of the 
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pilot studies involving these agents have shown 
improvement in metabolic biomarkers and his-
tology, these studies involved very small sample 
sizes.
III.3. Antioxidants 
III.3.1. Vitamin E has been shown to improve 
aminotransferases as well as histological markers 
in subjects with NASH. Some studies have also 
shown complete resolution of steatohepatitis, 
but there are mixed results on its effect on liver 
fibrosis. As described above in the pioglitazone 
section, the PIVENS trial, a randomized, multi-
center, double blind, placebo-controlled trial [9]. 
The effect of vitamin E on NAFLD has also been 
evaluated in many combination therapy stud-
ies. In a prospective, double-blind, randomized, 
placebo-controlled trial, 45 patients with biopsy 
proven NASH were enrolled to receive either vita-
min E 1000 IU plus vitamin C 1000mg or placebo 
for 6 months [3]. At the end of treatment, the 
vitamin E + C group had statistically significant 
improvement in fibrosis but no improvement in 
necroinflammation. Similar results were seen in a 
small study evaluating combination of vitamin E 
and pioglitazone compared to vitamin E alone.
III.3.2. Other Antioxidants. Changes in me-
thionine/folate metabolism may contribute to 
the development of steatosis. S-adenosyl methi-
onine (SAM) and betaine are nutritional supple-
ments that have anti-TNF alpha, cytoprotective, 
antiapoptotic, and antisteatogenic activity and 
can cause reversal of insulin resistance. N-acetyl 
cysteine (NAC) is a glutathione precursor, which 
increases glutathione in hepatocytes and limits 
the reactive oxygen species that causes hepato-
cellular injury.
III.4. Anti-Inflammatory Agents. Pentoxifyl-
line is a xanthine derivative that inhibits TNF 
alpha, which is a pro inflammatory cytokine 
that has been shown to activate reactive oxy-
gen species by lipid peroxidation and promote 
necroinflammation, fibrogenesis, hepatic insu-
lin resistance, and apoptosis. In a randomized 
placebo-controlled trial, 49 patients with biopsy 
proven NASH were randomized to pentoxifyl-
line versus placebo for 1 year. All patients in the 
treatment group had either improved NASH or 
no change. Compared to placebo, pentoxifylline 
group had significant improvement in Alanine 
aminotransferase (ALT), steatosis, inflammation, 
and fibrosis, but no change in ballooning. A de-
crease in NASH of ≥2 was seen in 50% of patients 
in pentoxifylline group versus 15,4% in placebo 
group. Additionally, 25% of NASH patients in the 
pentoxifylline group had resolution of NASH at 
the end of treatment.
III.5. Probiotics. Bacterial overgrowth in the 
bowel is present in 50% of patients with NASH 
and changes in the intestinal bacterial content 
may be related to the pathogenesis of NASH due 
to enhanced intestinal permeability, activation of 
inflammatory cytokines, and absorption of endo-
toxins. Therefore, probiotics have been suggested 
as a treatment option in NASH patients. However, 
some studies have shown worsening of steatosis 
with the use of probiotics.
III.6. Cytoprotective and Antiapoptotic Agents. 
Ursodeoxycholic acid (UDCA) has a beneficial ef-
fect on hepatobiliary diseases by its cytoprotective, 
immunomodulatory, and antiapoptotic effects. 
The efficacy results of UDCA on NAFLD/NASH have 
been mixed, with some trials showing improve-
ment in ALT and other histological mar kers such 
as steatosis, inflammation, and fibrosis.
III.7. Other Therapeutic Agents
III.7.1. Inhibitors of RAAS (Renin-Angio-
tensin-Aldosterone System). Emerging evidence, 
mainly in animal studies, has shown that inhibi-
ting RAAS pathway decreases hepatic stellate cell 
activity, which in turn prevents fibrosis and that 
ACE inhibitors and angiotensin receptor blockers 
may be useful in treating NAFL/NASH as they may 
lead to decreased fibrosis.
III.7.2. Coffee is rich in sources of bioactive 
phytochemicals including methylxanthines (caf-
feine), amino acids, phenolic acids, and polyphe-
nols, which may protect against liver disease. A 
study involved 195 patients participating in a 
questionnaire about coffee and espresso as well 
as other caffeinated drinks and chocolate. All pa-
tients underwent liver biopsies and compared to 
espresso, regular coffee consumption was associ-
ated with decreased odds ratio of liver fibrosis.
III.7.3. Vitamin D. There is not enough data 
assessing the effect of vitamin D supplementa-
tion on NAFLD, even though studies have shown 
vitamin D deficiency is associated with develop-
ment of NAFLD. A study of 60 patients with biopsy 
proven NAFLD and 60 healthy controls shows 
that, compared to controls, NAFLD patients had 
a significant decrease in vitamin D levels and that 
levels of vitamin D also negatively correlated with 
histological severity of steatosis, necroinflamma-
tion, and fibrosis independent of other variables 
or presence of metabolic syndrome.
III.7.4. Phlebotomy. Although there has been 
a significant recent interest in the role of iron in 
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NAFLD, the results have been conflicting. A recent 
study showed that patients who were suspected 
to have NAFLD had higher body iron and a greater 
hemoglobin level.
III.8. Antilipidemic Drugs
III.8.1 Statins. Statins is a class of drugs that 
lowers the level of cholesterol in the blood by 
reducing the production of cholesterol by the 
liver. (The other source of cholesterol in the blood 
is dietary cholesterol.) Statins block the hydroxy-
methylglutaryl-coenzyme A reductase (HMG-CoA 
reductase), enzyme in the liver that is responsible 
for making cholesterol. 
Statins are often underused in patients 
with non-alcoholic fatty liver disease and many 
physicians are concerned about the prescription 
of statins to patients with unexplained persistent 
elevation of liver enzymes or active liver disease. 
Based on currently available data, statin therapy, 
at low-to-moderate doses, seems to be safe and 
has low liver toxicity. Treatment of dyslipidaemia 
in patients with NAFLD is recommended and 
may also improve liver function tests. In these 
patients, the risks of not taking statins could out-
weigh the risks of taking the drug. Conversely, the 
usefulness of statins for the treatment of NAFLD 
/non-alcoholic steatohepatitis is still a matter of 
debate and randomized clinical trials of adequate 
size and duration are required [8].
Recently, the 2013 guidelines by the Ameri-
can College of Cardiology (ACC) and the American 
Heart Association (AHA) for the treatment of 
cholesterol expanded the indications for statin 
therapy for the prevention of cardiovascular 
disease in patient with NAFLD. Long-term use 
of statins results in important reductions in the 
risk of experiencing major coronary and vascular 
events in patients with a wide range of lipid levels, 
both in primary and secondary prevention.
Long-term statin treatment and liver toxicity
A. Liver toxicity of statins. Relevant statin-
related liver toxicity is a rare but important ad-
verse event occurring during statin treatment In 
fact, while asymptomatic elevations in serum ALT 
are relatively common in patients treated with 
statins, severe hepatic toxicity has been rarely 
described. During statin treatment, an asymp-
tomatic elevation in ALT should not be considered 
a sign of ongoing liver disease or injury.
Nevertheless, previous studies reported that 
statin use might induce an autoimmune hepatitis. 
In particular, some of a research described three 
cases of autoimmune hepatitis after treatment 
with fluvastatin – in two cases and atorvastatin 
– in one. 
B. Safety and efficacy of long-term statin treat-
ment in patients with abnormal liver tests. The issue 
of possible liver-related adverse effects of statin 
treatment in patients with coronary heart disease 
and liver enzyme elevation was addressed in a 
post hoc analysis of the Greek Atorvastatin and 
Coronary Heart Disease Evaluation (GREACE) 
Study. The frequency of liver-related adverse 
effects was low (1.1%) and did not differ from 
rates reported in patients not treated with statins 
(0.4%; p = 0.2). Additionally, 227 patients with 
abnormal rises in Aspartate aminotransferase 
(AST) or ALT concentrations of up to three times 
the upper limit of normal at entry in the trial, 
who were given a statin had a substantial im-
provement in liver tests during 3-year follow-up, 
whereas 210 not treated had a further increase 
of transaminases.
In conclusion, statins seem to be effective 
and safe for the treatment of hypercholestero-
lemia and/or atherogenic dyslipidaemiain pa-
tients with elevated serum liver enzymes, without 
inducing a further elevation of liver enzymes in 
treated patients.
C. Safety and efficacy of statins for the treat-
ment of dyslipidaemia in patients with non-alcoho-
lic fatty liver disease. Hyperlipidaemia is frequently 
associated with NAFLD. Most patients with mode-
rately elevated ALT levels have “atherogenic dys-
lipidaemia”, which is characterized by increased 
serum triglycerides, low high-density lipoprotein 
(HDL) cholesterol and the presence of small, 
dense Low-density lipoprotein (LDL) particles, 
a common finding also in insulin resistance and 
metabolic syndrome. “Atherogenic dyslipidae-
mia” is frequently associated with other features 
of metabolic syndrome such as obesity, diabetes 
mellitus, and hypertension. Aggressive treatment 
of dyslipidaemia plays a critical role in the overall 
management of patients with NAFLD.
However, there is concern that patients 
with NAFLD or NASH and hyperlipidaemia who 
are treated with statins could develop serum 
ALT elevation or a further increase of already 
elevated enzymes. Therefore, in clinical practice, 
management of dyslipidaemia in patients with 
NAFLD has been often a matter of concern and 
under-treatment with statin therapy because of 
potential liver damage. Safety of statin treatment 
of dyslipidaemia in patients with NAFLD has been 
addressed in numerous studies [1].
D. Safety and efficacy of statins for the treat-
ment of NAFLD and NASH. Statins have anti-
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inflammatory, anti-oxidant and anti-thrombotic 
effects that are independent of their lipid-low ring 
activity. Therefore, they have been proposed for 
the treatment of NAFLD and NASH, since in these 
conditions both inflammation and oxidative 
stress play an important pathogenetic role.
III.8.2 Dietary supplemens which reduce 
cholesterolemia
A relatively large number of dietary supple-
ments and nutraceuticals have been studied for 
their supposed or demonstrated ability to reduce 
cholesterolemia in humans. These supplements 
include soluble fibers, phytosterols, soy proteins, 
ω-3 polyunsaturated fatty acids, monacolins, 
policosanols, berberine and garlic extracts. 
Monocolins act as reversible inhibitors of 
the 3-hydroxy-3-methyl-glutaryl-coenzyme A 
(HMG-CoA) reductase, a key enzyme in choles-
terol biosynthesis. The main source of monocolins 
are Chinese red yeast rice (dietary supplement), 
made by fermenting the yeast, Monascus pur-
pureus, over rice. In addition to the inhibition 
of HMG-CoA reductase, red yeast rice has been 
found to contain sterols (β-sitosterol, campes-
terol, stigmasterol, and sapogenin), isoflavones 
and isoflavone glycosides, and monounsaturated 
fatty acids [2], all capable of lowering low-density 
lipoprotein cholesterol (LDL-C).
Several trials conducted in the People’s 
Republic of China showed that consumption of 
red yeast rice reduced cholesterol concentrations 
by 11–32% and triacylglycerol concentrations 
by 12–19%, both in animal and human models. 
These positive effects were also confirmed in an 
American population after 12 weeks of treatment 
and in a Norwegian population after 16 weeks 
of treatment, in two randomized, double-blind, 
placebo-controlled trials .
Summary, conclusion and perspective 
Due to the complex multi-factorial nature of 
the disease, combined treatment may be needed 
to achieve better results. Targeting cholesterol 
accumulation represents a potentially useful 
therapeutic approach in NAFLD. In patients with 
NAFLD, inhibition of cholesterol synthesis by 
statins alone or in combination with antioxidants 
was shown beneficial.
Unloading the liver from an excess of cho-
lesterol in the clinical setting would likely require 
a combination of dietary and pharmacological 
interventions that need to be designed and 
validated. Currently used drugs to treat hyperlipi-
demia may be of benefit in NAFLD/NASH but this 
specific effect warrants evaluation in large clinical 
trials. Also, new approaches targeting nuclear 
receptors or cholesterol metabolism pathways 
may become useful to reduce hepatic fatty thus 
reducing liver injury in NAFLD/NASH.
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